FDANews
FDAnews Drug Daily Bulletin

NICE OKs Opdivo for NHS Patients After Price-Cut Deal

Sept. 25, 2017

The UK’s drug-pricing regulator approved the purchase of Bristol-Myers Squibb’s Opdivo (nivolumab) at a discount for the country’s 1,300 eligible lung cancer patients through the government’s Cancer Drugs Fund.

The National Institute for Health and Care Excellence asked the company to reduce the price while clinical trials continue, after initially declaring the drug ineligible for purchase via the NHS.

Opdivo will be available to some patients in England with advanced non-small-cell lung cancer if they already have received chemotherapy, NICE said.

View today's stories